BloombergLean L·
Shionogi-Backed Apnimed Seeks to Raise $160 Million in US IPO
Apnimed Inc., a late-stage drug developer focused on sleep apnea, is seeking to raise as much as $160 million in a US initial public offering.
Read at Bloomberg →
Markets · 1 sources covering this
Shionogi-Backed Apnimed Seeks to Raise $160 Million in US IPO
Apnimed Inc., a late-stage drug developer focused on sleep apnea, is seeking to raise as much as $160 million in a US initial public offering.
Coverage spectrum
1 L · 0 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/74d17c6801536ea36283929ef6bfb694eb932b92" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Shionogi-Backed Apnimed Seeks to Raise $160 Million in US IPO"></iframe>
